Rheumatoid arthritis: Direct and indirect costs;Polyarthrite rhumatoïde : Coûts directs et indirects

Revue du Rhumatisme (Edition Francaise)

Volumn 71, Issue 12, 2004, Pages 1122-1129

  Rat, Anne Christine ^a   Boissier, Marie Christophe ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Costs; Health economics; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALYSIS OF VARIANCE; ARTHROPATHY; ARTICLE; CONSULTATION; DRUG COST; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; GEOGRAPHY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITAL CARE; HUMAN; JOINT PROSTHESIS; MORTALITY; PHYSICAL DISABILITY; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOID ARTHRITIS;

EID: 10944245404     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2004.01.003     Document Type: Article

References (47)

1. Gabriel S.E. Crowson C.S. O'Fallon W.M. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985 Arthritis Rheum 42 1999 415-420
2. Saraux A. Guedes C. Allain J. Devauchelle V. Valls I. Lamour A. et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Société de rhumatologie de l'Ouest J Rheumatol 26 1999 2622-2627
3. Pincus T. Sokka T. Wolfe F. Premature mortality in patients with rheumatoid arthritis: Evolving concepts Arthritis Rheum 44 2001 1234-1236
4. Yelin E. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates J Rheumatol Suppl 44 1996 47-51
5. Clarke A.E. Zowall H. Levinton C. Assimakopoulos H. Sibley J.T. Haga M. et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: A 12 year study J Rheumatol 24 1997 1051-1060
6. van Jaarsveld C.H. Jacobs J.W. Schrijvers A.J. Heurkens A.H. Haanen H.C. Bijlsma J.W. Direct cost of rheumatoid arthritis during the first six years: A cost-of-illness study Br J Rheumatol 37 1998 837-847
7. McIntosh E. The cost of rheumatoid arthritis Br J Rheumatol 35 1996 781-790
8. Blomqvist P. Feltelius N. Ekbom A. Klareskog L. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions J Rheumatol 27 2000 1171-1177
9. Magnusson S. Treatment of rheumatoid arthritis; does it affect society's cost for the disease? Br J Rheumatol 35 1996 791-795
10. Wolfe F. Hawley D.J. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients J Rheumatol 25 1998 2108-2117
11. Newhall-Perry K. Law N.J. Ramos B. Sterz M. Wong W.K. Bulpitt K.J. et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists J Rheumatol 27 2000 1156-1163
12. Yelin E. Wanke L.A. An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline Arthritis Rheum 42 1999 1209-1218
13. Clarke A.E. Levinton C. Joseph L. Penrod J. Zowall H. Sibley J.T. et al. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis J Rheumatol 26 1999 1068-1075
14. Stone C.E. The lifetime economic costs of rheumatoid arthritis J Rheumatol 11 1984 819-827
15. Kobelt G. Eberhardt K. Jonsson L. Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden Arthritis Rheum 42 1999 347-356
16. Kobelt G. Jonsson L. Lindgren P. Young A. Eberhardt K. Modeling the progression of rheumatoid arthritis: A two-country model to estimate costs and consequences of rheumatoid arthritis Arthritis Rheum 46 2002 2310-2319
17. Lubeck D.P. Spitz P.W. Fries J.F. Wolfe F. Mitchell D.M. Roth S.H. A multicenter study of annual health service utilization and costs in rheumatoid arthritis Arthritis Rheum 29 1986 488-493
18. Maravic M. Bozonnat M.C. Sevezan A. Gasqueres D. Pastor J. Pere M.et al. Preliminary evaluation of medical outcomes (including quality of life) and costs in incident RA cases receiving hospital-based multidisciplinary management Joint Bone Spine 67 2000 425-433
19. Merkesdal S. Ruof J. Huelsemann J.L. Schoeffski O. Maetzel A. Mau W. et al. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis J Rheumatol 28 2001 657-661
20. Ruof J. Merkesdal S. Huelsemann J.L. Schoeffski O. Maetzel A. Mau W. et al. Cost assessment instrument in rheumatology: Evaluation of applied instrument characteristics J Rheumatol 28 2001 662-665
21. Sany J. Dropsy R. Daures J.P. Cross-sectional epidemiological survey of rheumatoid arthritis patients seen in private practice in France. Descriptive results (1629 cases) Rev Rhum Engl Ed 65 1998 462-470
22. Gabriel S.E. Crowson C.S. Campion M.E. O'Fallon W.M. Direct medical costs unique to people with arthritis J Rheumatol 24 1997 719-725
23. Gabriel S.E. Crowson C.S. Campion M.E. O'Fallon W.M. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls J Rheumatol 24 1997 43-48
24. Sokka T. Pincus T. Markers for work disability in rheumatoid arthritis J Rheumatol 28 2001 1718-1722
25. Wolfe F. Kleinheksel S.M. Spitz P.W. Lubeck D.P. Fries J.F. Young D.Y. et al. A multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and charges Arthritis Rheum 29 1986 614-619
26. Ariza-Ariza R. Mestanza-Peralta M. Cardiel M.H. Direct costs of medical attention to Mexican patients with rheumatoid arthritis in a tertiary care center Clin Exp Rheumatol 15 1997 75-78
27. Ferraz M.B. Maetzel A. Bombardier C. A summary of economic evaluations published in the field of rheumatology and related disciplines Arthritis Rheum 40 1997 1587-1593
28. Birnbaum H.G. Barton M. Greenberg P.E. Sisitsky T. Auerbach R. Wanke L.A. et al. Direct and indirect costs of rheumatoid arthritis to an employer J Occup Environ Med 42 2000 588-596
29. Girard F. Guillemin F. Novella J.L. Valckenaere I. Krzanowska K. Vitry F. et al. Health-care use by rheumatoid arthritis patients compared with non-arthritic subjects Rheumatology (Oxford) 41 2002 167-175
30. Lanes S.F. Lanza L.L. Radensky P.W. Yood R.A. Meenan R.F. Walker A.M. et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: The importance of drug and surgery costs Arthritis Rheum 40 1997 1475-1481
31. Ethgen O. Kahler K.H. Kong S.X. Reginster J.Y. Wolfe F. The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: A longitudinal analysis J Rheumatol 29 2002 1147-1155
32. Meenan R.F. Anderson J.J. Kazis L.E. Egger M.J. Altz-Smith M. Samuelson C.O.Jr et al. Outcome assessment in clinical trials. Evidence for the sensitivity of a health status measure Arthritis Rheum 27 1984 1344-1352
33. Jacobs J. Keyserling J.A. Britton M. Morgan G.J.Jr Wilkenfeld J. Hutchings H.C. The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: The Medi-Cal program J Clin Epidemiol 41 1988 215-223
34. Jonsson B. Rehnberg C. Borgquist L. Larsson S.E. Locomotion status and costs in destructive rheumatoid arthritis. A comprehensive study of 82 patients from a population of 13,000 Acta Orthop Scand 63 1992 207-212
35. Guillemin F. Sibilia J. Daurès J.P. Durieux S. Lafuma A. Fagnani F. et al. Practis. étude médico-économique des caractéristiques et de la prise en charge de la PR à l'hôpital en France : Coûts de la polyarthrite rhumatoïde en France Rev Rhum 68 2001 C01
36. Griffiths R.I. Bar-Din M. MacLean C. Sullivan E.M. Herbert R.J. Yelin E.H. Patterns of disease-modifying antirheumatic drug use, medical resource consumption, and cost among rheumatoid arthritis patients Ther Apher 5 2001 92-104
37. Merkesdal S. Ruof J. Schoffski O. Bernitt K. Zeidler H. Mau W. Indirect medical costs in early rheumatoid arthritis: Composition of and changes in indirect costs within the first three years of disease Arthritis Rheum 44 2001 528-534
38. Cooper N.J. Mugford M. Scott D.G. Barrett E.M. Symmons D.P. Secondary health service care and second line drug costs of early inflammatory polyarthritis in Norfolk, UK J Rheumatol 27 2000 2115-2122
39. Leardini G. Salaffi F. Montanelli R. Gerzeli S. Canesi B. A multicenter cost-of-illness study on rheumatoid arthritis in Italy Clin Exp Rheumatol 20 2002 505-515
40. Pugner K.M. Scott D.I. Holmes J.W. Hieke K. The costs of rheumatoid arthritis: An international long-term view Semin Arthritis Rheum 29 2000 305-320
41. Wong J.B. Singh G. Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis Am J Med 113 2002 400-408
42. Kobelt G. Jonsson L. Young A. Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study Rheumatology (Oxford) 42 2003 326-335
43. Brennan A. Bansback N. Reynolds A. Conway P. Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Rheumatology 43 2004 62-71
44. Prashker M.J. Meenan R.F. The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity Arthritis Rheum 38 1995 318-325
45. Daurès J.P. Sibilia J. Guillemin F. Durieux S. Lafuma A. Fagnani F. et al. Practis. étude médico-économique des caractéristiques et de la prise en charge de la PR à l'hôpital en France : description de la méthodologie générale Rev Rhum 68 2001 C01
46. Sany J. Bourgeois P. Saraux A. Durieux S. Lafuma A. Fagnani F. et al. Practis. étude médico-économique des caractéristiques et de la prise en charge de la PR à l'hôpital en France : Aspects actuels de la polyarthrite rhumatoïde en France Rev rhum 68 2001 C01
47. Saraux A. Daurès J.P. Sany J. Durieux S. Lafuma A. Fagnani F. et al. Practis. étude médico-économique des caractéristiques et de la prise en charge de la PR à l'hôpital en France : Qualité de vie et caractéristiques socioprofessionnelles de patients atteints de PR en France Rev Rhum 68 2001 C01